# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
HC Wainwright & Co. analyst Douglas Tsao reiterates Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $25 pri...
On Tuesday before the market opened, Sage Therapeutics announced findings regarding Huntington's Disease (HD) based upon to...
Needham analyst Ami Fadia reiterates Sage Therapeutics (NASDAQ:SAGE) with a Hold.
Baird analyst Joel Beatty maintains Sage Therapeutics (NASDAQ:SAGE) with a Neutral and maintains $15 price target.
Citigroup analyst David Hoang initiates coverage on Sage Therapeutics (NASDAQ:SAGE) with a Sell rating and announces Price T...
Baird analyst Joel Beatty initiates coverage on Sage Therapeutics (NASDAQ:SAGE) with a Neutral rating and announces Price Ta...